Financhill
Buy
59

CLLS Quote, Financials, Valuation and Earnings

Last price:
$1.92
Seasonality move :
-14.33%
Day range:
$1.89 - $2.06
52-week range:
$1.10 - $2.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.08x
P/B ratio:
1.72x
Volume:
131.5K
Avg. volume:
104.1K
1-year change:
-8.29%
Market cap:
$199.6M
Revenue:
$41.5M
EPS (TTM):
-$0.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLLS
Cellectis SA
$11.7M -$0.15 39.85% -46.43% $5.75
ADAP
Adaptimmune Therapeutics PLC
$11.1M -$0.14 -91.39% -8.33% $1.45
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.94
DBVT
DBV Technologies SA
$747.8K -$0.18 -- -84.24% $16.06
EDAP
Edap TMS SA
$16.6M -$0.16 -2.39% -4.81% $5.75
GNFT
Genfit SA
$33.6M -- -- -- $8.70
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLLS
Cellectis SA
$1.99 $5.75 $199.6M -- $0.00 0% 4.08x
ADAP
Adaptimmune Therapeutics PLC
$0.27 $1.45 $71.6M -- $0.00 0% 0.39x
BDRX
Biodexa Pharmaceuticals PLC
$0.84 $17.94 $4.2M -- $0.00 0% 0.87x
DBVT
DBV Technologies SA
$9.79 $16.06 $267.8M -- $0.00 0% --
EDAP
Edap TMS SA
$1.47 $5.75 $55M -- $0.00 0% 0.82x
GNFT
Genfit SA
$3.84 $8.70 $191.8M 32.57x $0.00 0% 2.66x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLLS
Cellectis SA
30.41% 0.887 56.64% 1.64x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.289 50.03% 1.57x
BDRX
Biodexa Pharmaceuticals PLC
-- 2.010 -- 1.20x
DBVT
DBV Technologies SA
-- -2.552 -- --
EDAP
Edap TMS SA
17.49% -0.605 10.79% 1.16x
GNFT
Genfit SA
-- -0.504 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
EDAP
Edap TMS SA
$6M -$6.3M -43.34% -49.1% -44.23% -$6.6M
GNFT
Genfit SA
-- -- -- -- -- --

Cellectis SA vs. Competitors

  • Which has Higher Returns CLLS or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -170.14% compared to Cellectis SA's net margin of -653.18%. Cellectis SA's return on equity of -49.15% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About CLLS or ADAP?

    Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 188.95%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 437.5%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Adaptimmune Therapeutics PLC is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    1 2 0
    ADAP
    Adaptimmune Therapeutics PLC
    2 4 0
  • Is CLLS or ADAP More Risky?

    Cellectis SA has a beta of 2.910, which suggesting that the stock is 191% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.

  • Which is a Better Dividend Stock CLLS or ADAP?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or ADAP?

    Cellectis SA quarterly revenues are $10.7M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Cellectis SA's net income of -$18.1M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Cellectis SA's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.08x versus 0.39x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    4.08x -- $10.7M -$18.1M
    ADAP
    Adaptimmune Therapeutics PLC
    0.39x -- $7.3M -$47.6M
  • Which has Higher Returns CLLS or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About CLLS or BDRX?

    Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 188.95%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Cellectis SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    1 2 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is CLLS or BDRX More Risky?

    Cellectis SA has a beta of 2.910, which suggesting that the stock is 191% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

  • Which is a Better Dividend Stock CLLS or BDRX?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or BDRX?

    Cellectis SA quarterly revenues are $10.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Cellectis SA's net income of -$18.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.08x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    4.08x -- $10.7M -$18.1M
    BDRX
    Biodexa Pharmaceuticals PLC
    0.87x -- -- --
  • Which has Higher Returns CLLS or DBVT?

    DBV Technologies SA has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About CLLS or DBVT?

    Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 188.95%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    1 2 0
    DBVT
    DBV Technologies SA
    1 0 0
  • Is CLLS or DBVT More Risky?

    Cellectis SA has a beta of 2.910, which suggesting that the stock is 191% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

  • Which is a Better Dividend Stock CLLS or DBVT?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or DBVT?

    Cellectis SA quarterly revenues are $10.7M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of -$18.1M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.08x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    4.08x -- $10.7M -$18.1M
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns CLLS or EDAP?

    Edap TMS SA has a net margin of -170.14% compared to Cellectis SA's net margin of -52.18%. Cellectis SA's return on equity of -49.15% beat Edap TMS SA's return on equity of -49.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
  • What do Analysts Say About CLLS or EDAP?

    Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 188.95%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 291.16%. Given that Edap TMS SA has higher upside potential than Cellectis SA, analysts believe Edap TMS SA is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    1 2 0
    EDAP
    Edap TMS SA
    0 2 0
  • Is CLLS or EDAP More Risky?

    Cellectis SA has a beta of 2.910, which suggesting that the stock is 191% more volatile than S&P 500. In comparison Edap TMS SA has a beta of -0.003, suggesting its less volatile than the S&P 500 by 100.255%.

  • Which is a Better Dividend Stock CLLS or EDAP?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or EDAP?

    Cellectis SA quarterly revenues are $10.7M, which are smaller than Edap TMS SA quarterly revenues of $14.3M. Cellectis SA's net income of -$18.1M is lower than Edap TMS SA's net income of -$7.4M. Notably, Cellectis SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.08x versus 0.82x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    4.08x -- $10.7M -$18.1M
    EDAP
    Edap TMS SA
    0.82x -- $14.3M -$7.4M
  • Which has Higher Returns CLLS or GNFT?

    Genfit SA has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About CLLS or GNFT?

    Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 188.95%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 126.92%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    1 2 0
    GNFT
    Genfit SA
    1 0 0
  • Is CLLS or GNFT More Risky?

    Cellectis SA has a beta of 2.910, which suggesting that the stock is 191% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.244%.

  • Which is a Better Dividend Stock CLLS or GNFT?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or GNFT?

    Cellectis SA quarterly revenues are $10.7M, which are larger than Genfit SA quarterly revenues of --. Cellectis SA's net income of -$18.1M is higher than Genfit SA's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.08x versus 2.66x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    4.08x -- $10.7M -$18.1M
    GNFT
    Genfit SA
    2.66x 32.57x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock